Upcoming CME Events
-
New Directions in the Diagnosis and Treatment of Hematologic Cancers Hematologic malignancies research is growing at a rapid pace, increasing the complexity of the field. Advances in the understanding of the mechanisms of hematologic malignancies have resulted in the development of new prognostic models, novel therapies, and improvements in disease management. It is essential to our community to stay abreast of the latest findings in the field and of their potential impact on clinical practices.
This symposium will provide attendees with cutting-edge updates and perspectives on new diagnostic tools and management options of hematologic malignancies including genetic profiling, cytogenetics, molecular diagnostics, riskadaptive strategies, and novel therapies recently approved by the FDA. Advances in the understanding of aggressive/ indolent lymphoma, myelodysplasia, plasma cell dyscrasia, acute/chronic leukemia, and myeloproliferative disease will be addressed. Newer therapeutic approaches in classical hematology will also be reviewed.
DATE
Tuesday, April 16, 2024TIMES
5:45 – 9 PMPROGRAM DIRECTOR
Rashmi Khanal, MD
Assistant Professor,
Department of Bone Marrow Transplant and Cellular TherapiesFACULTY
Henry Fung, MD, FACP, FRCPE
Chair and Professor,
Department of Bone Marrow Transplant and Cellular Therapies
Zachary Frosch, MD, MSHP
Assistant Professor,
Department of Hematology/Oncology
Marcus Messmer, MD
Assistant Professor,
Department of Hematology/Oncology
Iberia Romina Sosa, MD, PhD
Chief, Division of Hematology; Associate Professor
Department of Hematology/Oncology
Michael Jay Styler, MD
Associate Professor,
Department of Bone Marrow Transplant and Cellular Therapies
Asya Nina Varshavsky-Yanovsky, MD, PhD
Assistant Professor,
Department of Bone Marrow Transplant and Cellular TherapiesInquiries
Lucía Tono, PhD, Med: 215-728-3797
[email protected]Intended Audience
The program is designed for oncologists, hematologists, radiation oncologists, pathologists, internists, primary care physicians, fellows, physician assistants, nurse practitioners, oncology nurses, and social workers.
Accreditation Statement
The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.
Designation Statement
The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity.
LEARNING OBJECTIVES
After participating in this educational program, learners should be able to:
• Summarize the findings from key clinical trials presented at the 2023 ASH meeting that will impact standards of care in hematology
• Discuss the latest findings in genetic profiling, cytogenetics, and molecular biology, and describe how this information can be utilized in determining patient prognosis and treatment course
• List novel, targeted therapies in development for hematology and explain the therapeutic rationale for these agents
• Describe the latest advances in the field of classical hematology that will impact patient treatment
• Outline the ways clinical trial data can be efficiently incorporated into community-based hematology practice -
2024 Atlantic Regional Hematopathology Meeting Abstracts are due Monday, March 25, 2024.
Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, this in-person education program is designed to focus on the role of molecular pathology and new technologies in diagnosis, prognostic stratification, and treatment of complex cases. Participants will gain insights into the significant changes, updates, and new categories in the 5th Edition of the World Health Organization Classification of Hematolympoid Tumors. Renowned invited pathologists and senior authors of the new WHO edition-Dr. Joseph Khoury, Dr. German Ott, and Dr. Sanam Loghavi-will discuss notable updates, modications, and new classifications in the morphology and molecular genetics of hematologic neoplasms that can be immediately applied in practice. As usual, there will be case-based podium presentations followed by discussion. A poster session will also take place.
We invite you to submit abstracts of clinical, scientific, and educational value with a focus on the role of molecular pathology and new technologies in the diagnosis, prognostic stratification, and treatment of challenging cases. To submit an abstract for consideration, please see flyer. Abstracts are due Monday, March 25, 2024.
DATE
Saturday, May 11, 2024TIMES
8:30 am- 4pmPROGRAM DIRECTOR
Reza Nejati, MD
Associate Professor
Medical Director of TUHS-FCCC Clinical Laboratories
Director, Flow Cytometry Lab
Department of Pathology
Fox Chase Cancer CenterKEYNOTE SPEAKERS
Joseph Khoury, MD
Professor and Head
Department of Pathology and Microbiology
University of Nebraska Medical Center
German Ott, MD
Professor & Chair,
Department of Clinical Pathology
Robert-Bosch Krankenhaus
Stuttgart, GermanyDISTINGUISHED GUEST SPEAKER
Sanam Loghavi, MD
Associate Professor
Department of Hematopathology
MD Anderson Cancer CenterInquiries
Lucía Tono, PhD, MEd: 215-728-3797
[email protected]Intended Audience
Hematopathologists, pathologists of other subspecialties, hematologists/oncologists, radiation oncologists, internists, primary care providers, fellows and residents of pathology, oncology and other specialties.
Accreditation Statement
The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.
Designation Statement
The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity.
It is the policy of the Temple Health Office for Continuing Medical Education to ensure that all sponsored continuing medical education activities are independently designed and produced and include content that is valid, objective, balanced, free of commercial bias and in the best interest to the public. Temple Health policy requires everyone in a position to control the content of an educational activity to disclose all financial relationships with ineligible companies and to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The Temple Health Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to the activity.